Why Healthcare Growth Stalls After the Deal
By Sarah Kerns, Founder, Harborline Growth Advisory
Most PE-backed healthcare companies do not stall because the market disappeared. They stall because the business outgrows the commercial model that created the first phase of success.
The founder relationships, individual seller performance, and informal operating processes that worked at $10 million in revenue often become constraints at $30 million, $50 million, or $100 million. At that stage, growth becomes less about effort and more about infrastructure.
The companies that continue to scale build a commercial operating system. The companies that do not often spend more, hire faster, and create more activity without improving revenue quality.
After 25 years leading growth across healthcare services, health systems, and PE-backed businesses, I have seen the same pattern repeatedly. The strategy is usually directionally right. Execution breaks down across five areas.
1. Growth is treated as a sales problem
When revenue slows, the first response is often to hire more salespeople. That may increase activity. It rarely fixes the underlying issue.
A scalable commercial model requires alignment across:
Market selection
Service design
Pricing
Sales execution
Operational capacity
Implementation
Account expansion
Executive accountability
Sales cannot consistently sell what operations cannot deliver. Operations cannot prepare for demand it cannot see. Finance cannot forecast accurately without a disciplined pipeline. Marketing cannot create demand without a clear value proposition.
Growth belongs to the entire leadership team. The commercial leader must connect these functions and create one operating cadence around revenue.
2. The company has customers, but no repeatable growth model
Many healthcare companies reach meaningful scale through strong relationships, founder credibility, referrals, and a few large accounts. That is a valuable starting point, but it is not a repeatable growth engine.
Leadership should be able to answer five questions clearly:
Which customer segments produce the strongest economics?
What specific problem creates urgency for the buyer?
Who owns the buying decision?
What steps consistently move an opportunity from interest to contract?
What must happen operationally for the customer to expand?
If the answers vary by salesperson, region, or customer, the business still relies on individual performance rather than a commercial system. A repeatable model does not eliminate judgment. It gives judgment structure.
3. Pipeline activity is confused with revenue visibility
A large pipeline can create false confidence. The more important questions are:
How much of the pipeline is qualified?
Which opportunities have executive sponsorship?
Where is the buyer in the decision process?
What operational dependencies could delay launch?
Which deals are likely to convert within the forecast period?
What is the expected value after implementation risk?
Healthcare sales cycles are complex. Decisions often involve clinical, operational, financial, legal, compliance, and executive stakeholders.
A credible forecast requires more than stage labels in a CRM. It requires a defined qualification standard, clear next steps, documented decision criteria, and leadership inspection.
The board should understand the difference between pipeline volume and revenue confidence.
4. Pricing has not evolved with the value proposition
Many healthcare businesses underprice their services because the original model was built to win early customers. Over time, the company adds capabilities, expands service levels, absorbs complexity, and takes on more accountability, yet pricing often remains largely unchanged. That compresses margin and makes growth more expensive.
Pricing should reflect:
Customer value
Clinical and operational complexity
Speed and service guarantees
Geographic coverage
Staffing risk
Implementation requirements
Reporting and technology capabilities
Strategic importance of the solution
The question is not simply whether the market will accept a higher price. The question is whether the company has clearly defined and communicated the value it creates.
Strong commercial leaders do not treat pricing as a finance exercise. They treat it as a strategic growth lever.
5. Leadership has not defined who owns growth
As companies scale, responsibility for growth often becomes fragmented. Sales owns new logos. Operations owns delivery. Account management owns retention. Marketing owns lead generation. Finance owns the plan. No one owns the full revenue system.
That creates gaps between contract signature, implementation, customer adoption, expansion, and renewal. A scalable model requires one executive view across the entire customer lifecycle.
That leader should have clear authority to:
Set commercial priorities
Align sales and operations
Establish pricing discipline
Build the revenue forecast
Define customer segmentation
Create accountability for expansion
Surface execution risk early
Translate market feedback into strategic decisions
Without that ownership, commercial performance becomes a collection of functional updates rather than an enterprise growth strategy.
What the CEO and board should expect
A strong commercial leader should bring more than a sales plan. The role should create clarity.
Within the first 90 days, the CEO and board should expect:
A fact-based assessment of the current growth engine
A clear view of the highest-value markets and customer segments
A realistic pipeline and revenue forecast
Defined commercial and operational constraints
A pricing and value proposition review
A clear account expansion strategy
A commercial scorecard tied to business outcomes
A sequenced plan for talent, systems, and execution
The objective is not to create more reporting. It is to improve decision quality. The commercial model should allow leadership to see where growth will come from, what could prevent it, and where capital and management attention should go.
The real test of commercial scale
A company has built a scalable growth engine when performance no longer depends on a few people working harder. It depends on the organization working better.
The business knows where to compete. The value proposition is clear. The sales process is disciplined. Operations can support demand. Pricing reflects value. Leadership sees risk early. Customers expand because the company consistently delivers.
That is the difference between growth that looks promising and growth that becomes durable enterprise value.
About the Author
Sarah Kerns is the founder of Harborline Growth Advisory and a healthcare commercial executive with more than 25 years of experience building and scaling revenue organizations. She advises PE-backed and founder-led healthcare companies on growth strategy, go-to-market execution, pricing, enterprise sales, and commercial leadership.
Comments